The FDA approved Genentech drug Xeloda (capecitabine)

, , ,

On April 30, 1998, the U.S. Food and Drug Administration (FDA) approved the Genentech’s drug Xeloda (capecitabine) for the treatment of adjuvant colon cancer, metastatic colorectal cancer and metastatic breast cancer.

Tags:


Source: U.S. Food and Drug Administration
Credit:

bioinnovatise accelerates scientific discovery by providing fast, reliable, and high-quality CDMO services for plasmid DNA and viral vector-based research.